I don't have a position in the company but are you trying to infer not to read too much into the press headlines and other findings in their PR, as it may be hyped up?
To date, 3 of 34 patients (9%) evaluable by RECIST achieved a confirmed partial response (PR)
I think that says more about RECIST than the drug. Results looks spectacular to me. Bone mets are likely the single most important problem for prostate cancer patients.
Market Data 
Markets 
AI
